People in the study are assigned by chance to receive either AZD0120 or one of the standard treatment plans used for this disease. The standard plans may include combinations such as daratumumab, carfilzomib, bortezomib, pomalidomide, and dexamethasone. AZD0120 is given through a vein, while the other treatments may be given by infusion, injection, or as capsules or tablets taken by mouth. The study then follows participants over time to see how the disease changes, how long the treatment effects last, and how safe the treatments are, with regular checks of general health and blood tests.

Participants in the study will be randomly assigned to receive either Belantamab Mafodotin or the combination of Pomalidomide and Dexamethasone. The study will monitor the participants over a period to see how well the treatments work in controlling the disease and to observe any side effects. The study will also look at how long the treatments can keep the disease from getting worse and how they affect the overall health and quality of life of the participants.

The trial will involve regular check-ups and tests to track the progress of the disease and the effects of the treatments. Participants will receive either the study medication or a placebo, which is a substance with no active drug, to compare the results. The study aims to provide valuable information that could help improve treatment options for people with relapsed or refractory multiple myeloma in the future.

Participants in this study will continue to receive isatuximab as they did in their previous study. The treatment will be administered either as a single therapy or alongside other medications, depending on what was used in the earlier study. The study will track any new side effects or health issues that arise during the treatment period. This will help researchers understand the long-term effects of isatuximab and ensure it remains safe for patients who continue to benefit from it.

The study will last for several years, allowing researchers to gather comprehensive data on the safety of isatuximab over an extended period. This information is crucial for determining the best ways to use isatuximab in treating multiple myeloma and ensuring that patients receive the most effective and safe care possible. Participants will be closely monitored by their healthcare providers throughout the study to ensure their well-being and to address any concerns that may arise during the treatment.

The treatment involves using belantamab mafodotin, which is given through an intravenous infusion, meaning it is delivered directly into a vein. This is used alongside mezigdomide, which is taken as an oral capsule. Additionally, dexamethasone, a type of steroid, is included in the combination therapy. During the study, participants will receive these medications according to a specific schedule to monitor how the cancer responds and to check for any side effects.

Participants in the study will be assigned to receive different combinations of medications. One group will receive Etentamig, which is given as an intravenous infusion, alongside Daratumumab. The other group will receive a combination of Daratumumab, Lenalidomide, and Dexamethasone. Dexamethasone is a type of steroid used to reduce inflammation, and Lenalidomide is an oral medication often used to treat cancer.

The study is divided into two main parts. The first part aims to find the correct amount of Etentamig to use when combined with Daratumumab. The second part compares the effectiveness of the Etentamig and Daratumumab combination against the standard treatment of Daratumumab, Lenalidomide, and Dexamethasone. During the study, participants will be monitored to see how the treatments affect the disease and to track any side effects.

The purpose of this study is to find out how safe these treatment combinations are and what side effects they might cause, and also to determine the best doses of etentamig when given alone or with other medicines. The study will also look at how well these treatments work in controlling the disease. Etentamig is given as an infusion, which means it is delivered directly into a vein over a period of time. Some of the other medicines are taken by mouth as capsules or tablets, while others are given as injections under the skin or into a vein.

During the study, participants will receive their assigned treatment combination and will be monitored regularly to check how they respond to the treatment and whether they experience any unwanted effects. The study team will measure things like whether the cancer responds to treatment, how long any response lasts, and how long participants remain without their disease getting worse. Some participants will receive treatment right after their diagnosis, while others will receive it as a maintenance therapy after other treatments, and some will receive it because their disease has returned or did not respond to earlier treatments. The specific treatment plan depends on which part of the study someone joins.

The purpose of this study is to find out if Linvoseltamab can eliminate the abnormal plasma cells that might turn into multiple myeloma and to determine the safest and most effective dose to use. The study will also look at how well people tolerate the medication and whether it causes any unwanted effects. In the first part of the study, different dose levels of Linvoseltamab will be tested in small groups to identify the highest dose that can be given safely. In the second part, a larger group of people will receive the selected dose to see how well it works at causing a complete response, which means the abnormal cells can no longer be detected.

During the study, participants will receive Linvoseltamab through infusions over a period of up to 27 months. Doctors will monitor participants closely for any side effects and will check blood samples to see if the treatment is working. The study will measure whether participants achieve a complete response, meaning all signs of the abnormal cells have disappeared, and whether this response lasts over time. Other measurements will include checking for minimal residual disease, which looks for very small amounts of abnormal cells that may still be present, and tracking how long people remain free from the disease getting worse. Blood tests will also be done to measure the amount of Linvoseltamab in the body and to check if the body develops antibodies against the medication.

The main purpose of this research is to evaluate how well patients respond to treatment over an 18-month period. The study specifically targets newly diagnosed patients who have not received any previous treatment and are considered frail according to medical assessment criteria. Patients will be divided into two groups – one receiving daratumumab with teclistamab, and the other receiving daratumumab with talquetamab.

During the study, patients will receive their assigned combination of medications through injections under the skin. The treatment will continue while monitoring how well the cancer responds and checking for any side effects. The medications work by helping the body’s immune system fight against the cancer cells. Regular medical check-ups and tests will be performed to track the progress of the treatment.

The treatment involves collecting the patient’s own T cells (a type of immune cell), which are then genetically modified in a laboratory to recognize and attack cancer cells. These modified cells are later given back to the patient through an intravenous infusion. The purpose of this study is to evaluate how well this treatment works when given with a modified preparation regimen that excludes a specific medication called fludarabine.

During the study, patients will receive their modified immune cells as a single infusion. The cells are stored in special freezing bags and will be thawed before being given to the patient. The treatment is part of a category of therapies known as cell therapy, which represents an advanced form of cancer treatment where the patient’s own immune system is enhanced to fight the disease.

The purpose of this study is to determine if this new cell therapy treatment is safe to use and if it works effectively against these blood cancers. The treatment is given as an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. This is a combined Phase 1 and Phase 2 study, where Phase 1 focuses on finding the right dose of the treatment, and Phase 2 examines how well the treatment works.

The treatment involves taking some of the patient’s own immune cells, modifying them in a laboratory to recognize and attack cancer cells, and then returning them to the patient through an infusion. After receiving the treatment, patients will be monitored for side effects and to see how their cancer responds to the therapy. The study specifically looks at patients whose cancer cells have a particular genetic marker called HLA-B*07:02.

The purpose of this research is to understand how safe and tolerable these medications are when given together, and to find the most appropriate dose combination for patients. During the study, patients will receive etentamig along with iberdomide capsules taken by mouth. Some patients will also receive iberdomide through an eye drop solution, while others will receive it through intravenous administration (given directly into a vein).

The study will monitor how patients respond to the treatment by checking if the cancer improves, stays the same, or gets worse. Doctors will track various aspects of the disease response, including how long the treatment works and whether any cancer cells remain in the body. Throughout the study, patients will have regular check-ups to monitor their health and any side effects from the treatment.

Multiple Myeloma is a type of blood cancer that affects plasma cells, which are special white blood cells that help fight infections. The study aims to determine which treatment combination is more effective at eliminating cancer cells to a level that cannot be detected by very sensitive testing methods.

The medications used in this study are given in different ways. Lenalidomide is taken by mouth in capsule form, while Daratumumab and Linvoseltamab are given through an infusion into a vein. Dexamethasone can be given either as tablets by mouth or as an injection. The treatment continues for several weeks, and patients will need regular visits to the hospital for monitoring and receiving their medications.

The main purpose is to understand how safe the new medication ABBV-453 is and how well patients tolerate it when used alone or combined with other multiple myeloma treatments. ABBV-453 belongs to a group of drugs called BCL-2 inhibitors, which work by blocking a protein that helps cancer cells survive.

During the study, patients will receive ABBV-453 tablets by mouth, either by itself or together with other medications that may be given as tablets or as injections under the skin. The study will monitor how patients respond to treatment and track any side effects that may occur. Doctors will regularly check patients’ blood and perform other medical tests to evaluate how well the treatment is working.

The purpose of the study is to find out the highest concentration of these biotherapy drugs that can be used in skin tests without causing irritation in patients who are not allergic. The study will involve skin tests, such as prick tests and intradermal tests, to check for any allergic reactions. Patients who have been treated with these biotherapies and have not shown any allergic reactions will be part of the study. The study will monitor for any immediate or delayed skin reactions after the tests.

Throughout the study, patients will be contacted to confirm if there are any delayed reactions, which might occur up to a week after the skin tests. If a reaction is suspected, a photograph or video consultation with an allergist may be used to confirm it. The study aims to ensure that the skin tests are safe and do not cause unnecessary irritation to patients undergoing biotherapy treatments.

The purpose of the study is to evaluate how safe and effective anitocabtagene autoleucel is for treating newly diagnosed multiple myeloma. Participants will receive this treatment after undergoing initial therapy, known as induction therapy, which helps to reduce the cancer cells before the main treatment. The study will monitor participants over time to see how well the treatment works and to check for any side effects. The study is designed to gather information on how the treatment affects the cancer and the overall health of the participants.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, with regular check-ups to monitor the participants’ health and the progress of the treatment. The goal is to understand the benefits and any potential risks associated with the treatment, providing valuable information for future use in treating multiple myeloma.

The purpose of this research is to determine if using elranatamab and lenalidomide together is more effective than current standard treatments for newly diagnosed multiple myeloma patients. The study is divided into two main phases: a consolidation phase, which follows initial treatment, and a maintenance phase, which aims to prevent the disease from returning.

During the study, patients will receive different combinations of medications through various methods, including oral capsules, tablets, and injections under the skin. Some medications will be given through an infusion into a vein. The treatment schedule will vary depending on which study group the patient is assigned to, and the total treatment period may last several months to years.

Participants in the study will receive CCS1477 in the form of a capsule taken by mouth. In some cases, it will be combined with other medications, such as Dexamethasone or Pomalidomide. The trial will monitor the safety and tolerability of these treatments, which means checking for any side effects and how well patients can handle the medication. The study will also look at how the drug is processed in the body and its potential effects on the cancer.

The trial will take place over several years, with regular check-ups and assessments to track the progress of the treatment. This includes looking at changes in the cancer through various tests and evaluations. The goal is to gather information on the drug’s safety and its impact on the cancer, which could help in developing new treatment options for these serious conditions.

The purpose of the study is to evaluate how effective and safe these two treatment combinations are for patients with newly diagnosed multiple myeloma. Participants in the study will be randomly assigned to receive one of the two treatment combinations. The study will monitor the participants over time to see how their disease responds to the treatment and to check for any side effects. The study will also look at how long the participants live without their disease getting worse and other health-related outcomes.

During the study, participants will receive their assigned treatment and will have regular check-ups to monitor their health and the progress of their disease. The study will continue for several years to gather enough information to determine which treatment combination is more effective and safer for patients with multiple myeloma. This research aims to improve treatment options for people with this type of cancer.

The purpose of the study is to compare the effectiveness of these two treatment combinations in helping patients maintain their health after a transplant. Participants in the study will receive one of the two treatment combinations and will be monitored over a period of time to see how well the treatments work. The study will look at various outcomes, such as how long patients remain free of disease progression and their overall survival rates.

Throughout the study, participants will have regular check-ups and assessments to monitor their health and the effects of the treatment. The study aims to provide valuable information on which treatment combination might offer better support for patients with newly diagnosed multiple myeloma after they have received a transplant. This research could help improve future treatment options for people with this condition.

The trial will test different combinations of medications to see how well they work in treating Multiple Myeloma. The medications being studied include Carfilzomib, Lenalidomide, Cyclophosphamide, and Dexamethasone. Carfilzomib is given as an infusion, which means it is administered directly into the bloodstream through a vein, while Lenalidomide, Cyclophosphamide, and Dexamethasone are taken orally in capsule form. The study will compare the effectiveness of these medications when used in different combinations and treatment plans, including before and after the transplant, or as a continuous treatment without a transplant.

The purpose of the study is to determine how effective these medication combinations are in achieving a significant reduction in cancer cells, known as a very good partial response, after four cycles of treatment. The study will also look at how long patients remain free from disease progression during the maintenance phase, where treatment is continued to help keep the cancer from returning. Participants will be monitored throughout the study to assess the outcomes of the different treatment approaches.

The purpose of the study is to evaluate how well this combination works in elderly patients who have experienced a second or further relapse of their multiple myeloma. Participants in the study will receive either the treatment combination or a placebo. The study will monitor the participants over a period of time to see how their condition responds to the treatment. The treatment will be administered either orally or through an intravenous infusion, depending on the specific medication.

Throughout the study, researchers will track the overall response rate, which means they will look at how many participants show improvement in their condition. They will also observe how long the response lasts, the time it takes for the disease to progress, and the overall survival of the participants. The study aims to provide valuable information on the potential benefits of using Melflufen and Dexamethasone together for treating relapsed multiple myeloma in elderly patients.

The purpose of this study is to determine if this treatment is safe and effective for patients with multiple myeloma. The study is divided into two phases. In the first phase, the focus is on assessing the safety of the treatment and finding the best dose to use in the second phase. The second phase will evaluate how well the treatment works in reducing the cancer. Participants will receive the treatment and be monitored over time to see how their bodies respond. This includes checking for any side effects and measuring the treatment’s impact on the cancer.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of the treatment. The study aims to provide valuable information on the potential of SLAMF7 CAR-T cells as a treatment option for multiple myeloma, offering hope for improved outcomes in the future. The trial is expected to continue until 2027, allowing researchers to gather comprehensive data on the long-term effects and benefits of this innovative therapy.

The study is divided into two phases. In the first phase, different doses of IDP-121 will be given to patients to determine the highest dose that can be safely administered. This is known as the dose-escalation phase. In the second phase, the study will focus on how effective the recommended dose is in treating the cancers. This phase will look at how many patients respond to the treatment and how long the response lasts.

Throughout the study, patients will receive regular check-ups to monitor their health and the effects of the treatment. This includes checking vital signs, conducting physical exams, and performing various tests like blood tests and heart monitoring. The study aims to gather information on how the treatment affects the body and how long patients can live without the cancer getting worse. Safety and any side effects will also be closely observed to ensure the well-being of the participants.

The purpose of the study is to evaluate how well these treatments work in achieving a state called MRD negativity, which means no minimal residual disease is detected, three years after starting the treatment. Patients with intermediate-risk smoldering multiple myeloma will receive a combination of dexamethasone and lenalidomide, while those with high-risk smoldering multiple myeloma will receive all three medications: dexamethasone, lenalidomide, and carfilzomib. The study will also look at the safety of these treatments and their overall effects on the disease.

Participants in the study will follow a treatment plan over a period of time, with regular check-ups to monitor their health and the progress of the disease. The study aims to provide valuable information on the effectiveness of these treatments in managing multiple myeloma and improving patient outcomes. The trial is expected to continue until 2027, with the goal of better understanding how these medications can help patients with this condition.

Participants in the study will be divided into two groups. One group will receive the Daratumumab treatment, while the other group will be observed without receiving the medication. The study will compare how long patients in each group remain free from new symptoms or complications related to Multiple Myeloma. This period is referred to as event-free survival (EFS). The study aims to determine if Daratumumab can extend the time patients remain without new cancer symptoms or other serious health issues.

The trial will monitor patients over a period of time to assess the effectiveness of Daratumumab in preventing the progression of Multiple Myeloma. The study will also look at the overall response rate, which measures how many patients experience a reduction in cancer signs. This information will help researchers understand if Daratumumab is a beneficial preventive treatment for patients with minimal residual disease or biochemical relapse of Multiple Myeloma.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for a period of up to 24 months, during which participants will receive their assigned treatment. The study will monitor the response to the treatment, focusing on the status of the disease at 12 months and the progression-free survival, which refers to the length of time during and after the treatment that the patient lives with the disease without it getting worse. The study will also look at the safety and tolerability of the treatments.

Throughout the study, participants will undergo regular assessments to track their health and the effectiveness of the treatment. These assessments will help determine how well the treatments work in achieving a complete response, where no signs of cancer are found, and maintaining this response over time. The study aims to provide valuable information on the best treatment options for patients with newly diagnosed Multiple Myeloma.

The purpose of this study is to determine if this combination of medications is safe and effective for treating patients with newly diagnosed multiple myeloma. The study will evaluate how well patients tolerate the treatment and measure how well the cancer responds to these medications when used together.

The treatment involves taking some medications by mouth (lenalidomide, dexamethasone, and nirogacestat) and receiving belantamab mafodotin through an intravenous infusion (through a vein). During the study, participants will receive regular medical check-ups and tests to monitor their health and evaluate how well the treatment is working. The study will last approximately four years.

The main purpose of this research is to determine if this combination of medications is safe and effective for patients whose disease has returned after receiving one to three previous treatments, particularly in cases where a medication called lenalidomide is no longer working. The study is divided into two parts, with the first part focusing on finding the right dose and checking safety, while the second part looks at how well the treatment works.

During the study, participants will receive the medications through different methods – some are given as capsules by mouth, while others are administered through injections into the veins or under the skin. The doctors will monitor patients’ responses to the treatment and check for any side effects, with particular attention to effects on vision. The study will continue to follow patients to measure how long the treatment remains effective and how it affects survival.

The purpose of the study is to find the best dose and schedule for these medications when used together. Participants will receive these treatments over a period of time, and researchers will monitor their health to see how well the treatment works and to check for any side effects. The study will be conducted in two parts: the first part will focus on finding the right dose, and the second part will further evaluate the treatment’s safety and effectiveness.

Throughout the study, participants will be closely observed by healthcare professionals. They will receive the medications either by mouth or through an injection into a vein, depending on the specific drug. The trial aims to provide valuable information that could lead to better treatment options for people with multiple myeloma in the future.

The main purpose of this study is to determine how well the combination of these medications improves kidney function in patients who have both multiple myeloma and severe kidney problems. The treatment consists of two phases: first, patients receive a combination of four medications through different methods – some given by injection into a vein, some taken by mouth, and one given under the skin. After this initial phase, patients continue with maintenance treatment using two medications.

The medications work in different ways to fight the cancer cells: Isatuximab is an antibody that targets specific proteins on cancer cells, Bortezomib helps block cancer cell growth, Cyclophosphamide is a chemotherapy drug that kills cancer cells, Dexamethasone is a steroid that reduces inflammation, and Lenalidomide helps the immune system fight cancer cells. The study will last for up to 36 months for each patient.

Participants in the study will receive their assigned treatment over a period of time, with regular check-ups to monitor their health and the progress of the disease. The study will look at how long patients live without the disease getting worse, as well as other factors like overall survival and quality of life. The trial will also collect information on any side effects experienced by participants to ensure the safety of the treatments being tested.

This study is important for understanding how to best treat Multiple Myeloma in patients who are considered frail and cannot undergo more aggressive treatments. By comparing these two treatment options, researchers hope to find a more effective way to manage the disease and improve the quality of life for those affected. Participants will be closely monitored throughout the study to ensure their safety and well-being.

The main purpose of this research is to evaluate how well patients respond to this three-drug combination during the first six months of treatment. The study will measure how the disease responds to treatment and track the overall health outcomes of participants. Patients will receive treatment for up to 42 months, depending on how well they respond to the medications.

During the study, doctors will regularly monitor patients’ blood counts, kidney and liver function, and assess how well the treatment is working. They will also track any side effects that may occur during treatment. After completing treatment, patients will continue to have follow-up visits to monitor their long-term health status.

Participants in the study will receive either the combination of BL-8040 and G-CSF or a placebo with G-CSF. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. The treatment involves injections, and the study will monitor how well the body can produce and collect stem cells over a couple of sessions. The goal is to collect a certain number of stem cells that are needed for the transplantation process.

The study will also look at how quickly the body recovers after the transplantation, focusing on how fast the blood cells return to normal levels. This includes checking the recovery of white blood cells and platelets, which are important for fighting infections and preventing bleeding. The study will follow participants for several months after the transplantation to see how well the stem cells continue to work in the body. This research aims to improve the treatment process for patients with Multiple Myeloma by making stem cell collection more effective and efficient.

The purpose of this study is to evaluate how effective the combination of these medications is in treating elderly patients who have been newly diagnosed with Multiple Myeloma. Participants in the study will receive these medications through injections or capsules over a period of time. The study will monitor the participants’ responses to the treatment, looking for improvements in their condition. The study will also keep track of any side effects that may occur during the treatment.

Throughout the study, participants will undergo regular check-ups to assess their health and the progress of the treatment. The study aims to determine if the combination of these medications can provide a significant benefit to patients with Multiple Myeloma, potentially leading to better treatment options in the future. The study is expected to continue for several years to gather comprehensive data on the effectiveness and safety of the treatment.

Participants in the study will receive talquetamab and may also be given other treatments to help manage any taste changes. These additional treatments include Pregabalin, which is a medication often used to treat nerve pain, Dexamethasone in the form of a mouthwash, and Clonazepam, which is a tablet that dissolves in the mouth. Some participants may receive a placebo instead of these additional treatments. The study will monitor how these treatments affect the taste changes caused by talquetamab over time.

The study will take place over several months, during which participants will be regularly assessed to see how their taste changes and if it improves with the treatments provided. The goal is to better understand and manage the taste changes associated with talquetamab, making the treatment experience more comfortable for patients with multiple myeloma.

The purpose of the study is to evaluate the safety and effectiveness of these treatments in patients with Multiple Myeloma. The study is divided into different parts, each focusing on specific combinations of medications. For example, one part of the study looks at the combination of Cevostamab and Lenalidomide in patients who have high-risk features and are receiving maintenance treatment after their first response to therapy. Another part examines the combination of Cevostamab and Iberdomide in patients whose disease has returned or is not responding to previous treatments.

Participants in the study will receive the study medications and be monitored for their response to the treatment and any side effects. The study aims to gather information on how well the treatments work and how safe they are for patients with Multiple Myeloma. This information will help in understanding the potential benefits and risks of these treatments for patients with this condition.

Participants in the study will receive Dexamethasone in one of its available forms, and their progress will be monitored over a period of time. The study aims to see if the treatment can help achieve a significant response in patients, which means either a complete or partial reduction of the disease symptoms. The study is designed to compare the effectiveness of Dexamethasone with other treatment options available for Multiple Myeloma.

The trial will involve several cycles of treatment, and the response of the patients will be assessed using specific criteria set by experts in the field. This study is important for understanding how Dexamethasone can be used effectively in treating Multiple Myeloma and may provide valuable insights into improving treatment strategies for this condition.

The purpose of this study is to determine which treatment combination works better in treating patients with relapsed or refractory Multiple Myeloma. The medications are given in different ways – some are taken by mouth as tablets or capsules, while others are given through injection under the skin or into a vein. The treatment will continue as long as it remains beneficial for the patient and side effects are manageable.

During the study, doctors will monitor how well the treatments work by checking the amount of cancer cells in the blood and bone marrow. They will also track how long patients live without their disease getting worse and evaluate the overall survival of patients receiving these treatments. Throughout the study, patients will have regular check-ups to monitor their health and any side effects from the treatments.

The purpose of the study is to evaluate how well these medications work together in treating patients with relapsed multiple myeloma. Participants in the study will receive these medications through intravenous infusions, which means the drugs are delivered directly into the bloodstream through a vein. The study will also include a process called autologous hematopoietic stem cell transplantation, where a patient’s own stem cells are used to help restore healthy blood cells after treatment.

Throughout the study, participants will be monitored to assess the response to the treatment and any side effects. The study aims to determine the rate of minimal residual disease (MRD) negativity, which indicates the absence of cancer cells in the body, within 12 months after the stem cell transplantation. The trial will also look at other outcomes, such as the overall response rate and the time it takes for the disease to progress. The study is expected to continue until early 2027.

The purpose of the study is to compare the effectiveness and safety of two different treatment combinations. One group will receive Elranatamab, Daratumumab, and Lenalidomide, while the other group will receive Daratumumab, Lenalidomide, and Dexamethasone. The study will follow participants over a period of time to see how well the treatments work and to monitor any side effects. Participants will receive their treatments either as tablets, capsules, or injections, depending on the medication.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of their treatment. The study aims to find out which combination of treatments is more effective in managing Multiple Myeloma for those who are not eligible for a transplant. This research is important for improving treatment options and outcomes for patients with this condition.